Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sci PharmtechTPE:4119 -0.19%75 EV-to-EBITDA is 21.28 as of Aug. 22, 2026, which is 78% above its 10-year median of 11.93. GuruFocus rates TPE:4119 with a GF Score™ of 75/100 and a GF Value™ of NT$74.29 (Possible Value Trap). The stock has 10 warning signs investors should review. Among 739 Drug Manufacturers companies, Sci Pharmtech ranks worse than 69.82% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Sci Pharmtech's enterprise value is NT$7,227 Mil.
Sci Pharmtech's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$340 Mil. Therefore, Sci Pharmtech's EV-to-EBITDA for today is 21.28.
The historical rank and industry rank for Sci Pharmtech's EV-to-EBITDA or its related term are showing as below:
TPE:4119'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -40.64 Med: 11.93 Max: 162.62
Current: 21.27
During the past 13 years, the highest EV-to-EBITDA of Sci Pharmtech was 162.62. The lowest was -40.64. And the median was 11.93.
TPE:4119's EV-to-EBITDA is ranked worse than 69.82% of 739
companies
in the Drug Manufacturers industry
Industry Median: 12.97
vs TPE:4119: 21.27
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sci Pharmtech's PE Ratio (TTM) for today is calculated as:
Sci Pharmtech's share price for today is NT$52.30.
Sci Pharmtech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0.510.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Sci Pharmtech's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sci Pharmtech's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sci Pharmtech EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sci Pharmtech's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Sci Pharmtech's EV-to-EBITDA falls into.
Sci Pharmtech's current Enterprise Value is NT$7,227 Mil.
Sci Pharmtech's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$340 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sci Pharmtech (TPE:4119) has a EV-to-EBITDA of 21.28 as of Aug. 22, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Sci Pharmtech. This is 78% above median its historical median of 11.93. According to the industry distribution chart, Sci Pharmtech ranks #516 out of 739 companies in the Drug Manufacturers industry, placing it in the top 69.8%.
Is Sci Pharmtech's EV-to-EBITDA too high?
Sci Pharmtech's current EV-to-EBITDA of 21.28 is 78% above median its 10-year median of 11.93. The Drug Manufacturers industry median EV-to-EBITDA is 12.97. Sci Pharmtech's value of 21.28 is 64.1% above this industry median. Based on the distribution chart, Sci Pharmtech ranks #516 out of 739 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Sci Pharmtech has a GF Score™ of 75/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sci Pharmtech's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sci Pharmtech ranks #516 out of 739 companies for EV-to-EBITDA. This places Sci Pharmtech in the lower half of its industry. The industry median EV-to-EBITDA is 12.97. Sci Pharmtech's value of 21.28 is 64.1% above this benchmark. While the company's 10-year median is 11.93 vs. the industry median of 12.97, Sci Pharmtech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.97, based on 739 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sci Pharmtech's current EV-to-EBITDA of 21.28 is 64.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Sci Pharmtech. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sci Pharmtech's current EV-to-EBITDA is 21.28, which is 78% above median its own 10-year median of 11.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sci Pharmtech stock overvalued right now?
Based on GuruFocus' analysis, Sci Pharmtech (TPE:4119) is currently considered Possible Value Trap. The stock's GF Value™ is NT$74.29, compared to a current price of NT$52.30 — trading 29.6% below its estimated fair value. The current EV-to-EBITDA is 21.28, which is 78% above median its 10-year median of 11.93 and 64.1% above the Drug Manufacturers industry median of 12.97. Sci Pharmtech's overall GF Score™ is 75/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Sci Pharmtech (TPE:4119), the current EV-to-EBITDA is 21.28 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sci Pharmtech (TPE:4119) Overvalued in 2026?
Based on GuruFocus' analysis, Sci Pharmtech stock appears to be undervalued.
The current stock price of NT$52.30 is trading 29.6% below its estimated GF Value™ of NT$74.29.
GuruFocus considers Sci Pharmtech to be Possible Value Trap.
Key valuation signals for TPE:4119:
EV-to-EBITDA: 21.28 (78% above median its 10-year median of 11.93)
GF Value™: NT$74.29 vs. price of NT$52.30 (29.6% below fair value)
Industry Position: 64.1% above the Drug Manufacturers median (#516 of 739)
No single metric tells the full story. See the TPE:4119 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sci Pharmtech Inc is engaged in the research and development, manufacture, and sales of active pharmaceutical ingredients, intermediates, and specialty chemicals. Geographically, the primary markets of the company are Italy, Germany, Japan, Taiwan, the United States, Switzerland, Spain, Belgium, Netherlands, and others.
75GF Score
Get the complete analysis for TPE:4119
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4119 has been successfully added to your 
